Literature DB >> 1707566

The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity.

A J Macadam1, S R Pollard, G Ferguson, G Dunn, R Skuce, J W Almond, P D Minor.   

Abstract

Intratypic recombinants of P2/Sabin and P2/117, a neurovirulent vaccine revertant, have been generated in vitro using infectious cDNA clones and used to demonstrate that strong determinants of the attenuation and temperature-sensitive phenotypes of P2/Sabin reside in the 5' 492 nucleotides. In this region of the genome the viruses differ only at nucleotides 437 and 481. The ts phenotype associated with the 5' noncoding region is expressed at different temperatures in different cell lines, suggesting an involvement of cellular factors which may be species specific. Suppression of both the ts and attenuation phenotypes correlates with an A-G mutation at nucleotide 481, although other changes are also involved.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707566     DOI: 10.1016/0042-6822(91)90877-e

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  41 in total

1.  Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus.

Authors:  T Kanno; D Mackay; T Inoue; G Wilsden; M Yamakawa; R Yamazoe; S Yamaguchi; J Shirai; P Kitching; Y Murakami
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Neurovirulence of type 1 polioviruses isolated from sewage in Japan.

Authors:  Hitoshi Horie; Hiromu Yoshida; Kumiko Matsuura; Miwako Miyazawa; Yoshihiro Ota; Takashi Nakayama; Yutaka Doi; So Hashizume
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

3.  A single base deletion in the 5' noncoding region of Theiler's virus attenuates neurovirulence.

Authors:  A E Pritchard; M A Calenoff; S Simpson; K Jensen; H L Lipton
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

5.  Differential recruitment of B and T cells in coxsackievirus B4-induced pancreatitis is influenced by a capsid protein.

Authors:  A I Ramsingh; W T Lee; D N Collins; L E Armstrong
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain.

Authors:  A J Macadam; G Ferguson; C Arnold; P D Minor
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

8.  Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor.

Authors:  Akiko Yanagiya; Seii Ohka; Noriyasu Hashida; Masahito Okamura; Choji Taya; Nobuhiko Kamoshita; Kuniko Iwasaki; Yukari Sasaki; Hiromichi Yonekawa; Akio Nomoto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Structure of the 5' nontranslated region of the coxsackievirus b3 genome: Chemical modification and comparative sequence analysis.

Authors:  Jennifer M Bailey; William E Tapprich
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses.

Authors:  N M Chapman; Z Tu; S Tracy; C J Gauntt
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.